Generic Name and Formulations:
Telotristat ethyl 250mg; tabs.
Indications for XERMELO:
In combination with somatostatin analog (SSA) therapy, to treat carcinoid syndrome diarrhea in adults inadequately controlled by SSA therapy.
Take with food. 250mg 3 times daily.
Monitor for constipation and/or severe, persistent, or worsening abdominal pain; discontinue if develops. ESRD requiring dialysis: not studied. Pregnancy. Nursing mothers: monitor infant for constipation.
May antagonize CYP3A4 substrates (eg, midazolam); monitor and consider increasing dose of concomitant substrates if necessary. Antagonized by short-acting octreotide; if concomitant use is necessary, give dose ≥30mins after Xermelo.
Tryptophan hydroxylase inhibitor.
Nausea, headache, increased GGT, depression, flatulence, decreased appetite, peripheral edema, pyrexia.
Monthly carton—4 x 7 daily dose packs